Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elezanumab in Relapsing MS
NCT03737851Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2018
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of elezanumab in multiple sclerosis (MS) (3 arms), sponsored by AbbVie Inc. Primary endpoint: Overall Response Score at 52 weeks. Started Dec 2018; status: completed.
02
Drugs
elezanumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03737851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03737851.